2018 2nd Quarter Memo for Vailshire Capital Management LLC

Dear clients and friends of Vailshire–   Happy Independence Day week! I hope you have been enjoying the freedom that we are blessed with in this country. And for those Vailshire clients and friends who are serving or have served in the military… thank you very much! 2018 2nd Quarter Investment Highlights   World politics remain turbulent, due–in no small part–to the persistent …

2018 1st Quarter Memo for Vailshire Capital Management LLC

Dear clients and friends of Vailshire–   I hope that all is well with you, wherever in the world this memo finds you! 2018 1st Quarter Investment Highlights   Volatility has (finally) returned. Normally a staple in the marketplace, volatility was conspicuously absent for the vast majority of 2017. If you pay any attention to financial media or literature, I am sure …

Celgene: The Best Buy-And-Hold Large-Cap Biotech For The Next Decade

Vailshire's Hedge fund manager, Jeff Ross, MD, recently published an article on SeekingAlpha.com: Summary CELG is the top large cap biotech stock pick for Vailshire.com. REVLIMID sales have incredible momentum and sales are actually accelerating in the U.S. and internationally. CELMoDs may provide life beyond REVLIMID's loss of patent protection in the 2020s.   It is no secret that Celgene ...

Vailshire Clients Quarterly Memo Apr 4, 2016

Dear clients of Vailshire- The first three months of 2016 have once again felt like a rollercoaster ride. Through mid-February, fear was rampant and the equities market descended into what felt like the land of no return. Bears (pessimists) took to CNBC, newspapers and newsletters around the world and triumphantly explained why this was not just going to be 2008 …

Vailshire Clients Quarterly Memo Jan 3, 2016

Memo to: Vailshire Clients From: Jeffrey W. Ross, MD, RIA Date: January 3, 2016 Eyes on the Prize For the majority of investors, 2015 was a difficult year. The S&P 500, Dow Jones Industrial Average, most foreign equities and most commodities all notched losses for the year. Neither Vailshire Capital Management nor its clients are surprised or overly concerned with …

When Bad News is Good News

Memo  to:   Vailshire  Clients From:     Jeffrey  W.  Ross,  MD,  RIA Date:     October  1,  2015   When  Bad  News  is  Good  News Warren  Buffett,  considered  by  many  to  be  the  greatest  investor  to  have  ever  lived,   has  said,  “Bad  news  is  the  friend  of  the  long-­‐term  investor.” This  is  because  bad  news—whether  brought  about  by …

The Big Mac Is Dead – Beef Up Your Portfolio With Nathan’s Famous Hot Dogs Instead

Originally posted on Seeking Alpha Summary It’s time to make the move from hamburgers to hot dogs. Sustained growth of revenues and earnings makes Nathan’s Famous Inc a compelling stock to own. Insider ownership makes a huge difference in terms of shareholder-friendliness. The Eulogy McDonald’s (NYSE:MCD) investors have long enjoyed tremendous returns, thanks to billions and billions of burgers served …

Invest Like Vailshire: Taro Pharmaceutical Industries Ltd Is A Hidden Gem

Originally published on Seeking Alpha Summary Generic drug makers have significant upside potential. TARO is an unheralded hidden gem. Taro Pharmaceuticals Industries Ltd’s consistent high growth of revenues and earnings, while trading at a cheap price, is a powerful investment combination. Setting the Stage If you spend any time in the healthcare equities arena then you have undoubtedly heard of …

Time to Sell or Time to Buy?

Time to Sell or Time to Buy? Wise shoppers know that the very best time to get good deals on your favorite items is during the unexpected “blue light specials” (or equivalent) that many retailers offer. The stock market acts in similar fashion… Don’t let short term market drops and intense volatility turn you into a short-term, fear-driven trader! Instead, …